April 1st 2024
Acceptance of the IND application would initiate a first-in-human phase 1 dose expansion and escalation trial of CTIM-76 in patients with testicular and gynecologic cancers.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
‘BCG-unresponsive’ definition bolstered by study
February 1st 2018Patients with bacillus Calmette-Guérin-unresponsive bladder cancer had worse clinical outcomes than patients who relapsed but did not meet BCG-unresponsive criteria, according to results of a retrospective analysis presented at the 2017 Society of Urologic Oncology annual meeting in Washington.
[Quiz] Abdominal pain after laparoscopic nephrectomy
December 15th 2017A 46-year-old male underwent a left laparoscopic radical nephrectomy for a cT1b renal cell carcinoma. Intra-operatively, a rent in the descending mesocolon was made during bowel mobilization but was not closed. Subsequently, the patient presented to the emergency room 4 days later with complaints of sudden onset sharp abdominal pain and nausea. A non-contrast computed tomography scan was obtained. What is the diagnosis?
Trimodal Tx may benefit some bladder Ca patients
November 3rd 2017Trimodal therapy could offer superior overall survival versus radical cystectomy in certain subsets of patients with bladder cancer, according to a retrospective analysis presented at the 2017 Society of Urologic Oncology annual meeting in Washington.
Blue light cystoscopy improves bladder Ca detection
October 6th 2017Blue light flexible cystoscopy (D-Light C PDD Flexible Videoscope System) with intravesical hexaminolevulinate HCl (HAL [Cysview]) for surveillance in the office setting significantly improved the detection of recurrent bladder tumors compared with white light cystoscopy.
Penile/Urethral Ca: Low adherence to lymph staging guidelines seen
July 6th 2017Other take-home messages in penile/urethral cancer included discussion of proposed 2018 AJCC penile cancer guidelines as well as the finding that in women with primary urethral cancer, adenocarcinoma was the most common pathology.
Prostate Ca immunotherapy induces T-cell response
June 30th 2017A study aimed at further elucidating the mechanism of action of sipuleucel-T (Provenge) in advanced prostate cancer provides fairly convincing evidence that the immunotherapy agent induces T-cell responses in humans, says Charles G. Drake, MD, PhD.
Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drug
June 27th 2017Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.